{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:39:20Z","timestamp":1793374760421,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tuberculosis (TB) remains the foremost cause of death from infectious diseases globally, prompting ongoing efforts to improve treatment options. This includes developing compounds with novel modes of action and identifying optimal treatment regimens that allow for treatment shortening. One promising strategy involves targeting cytochrome\n                    <jats:italic>bc<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    oxidase in\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    , a key enzyme in the respiratory chain. In this study, we evaluate the potential of cytochrome\n                    <jats:italic>bc<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    inhibitors as partner drugs in TB combination regimens. Using a relapsing mouse model, we demonstrate that these inhibitors enhance regimen sterilisation and significantly reduce the time required for effective treatment. We also propose several novel combination strategies for both multidrug-resistant and drug-sensitive TB, where cytochrome\n                    <jats:italic>bc<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    inhibitors contribute to sterilisation and improved treatment outcomes. Furthermore,\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    clinical isolates exhibited heightened susceptibility to cytochrome\n                    <jats:italic>bc<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    inhibitors compared to laboratory-adapted strains, highlighting the importance of using clinical isolates in TB drug discovery to better reflect the diversity of TB populations. These findings emphasise the potential of cytochrome\n                    <jats:italic>bc<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    inhibition in the development of more effective and shorter treatment regimens for TB, supporting the need for further clinical investigation.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-64427-6","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:22:58Z","timestamp":1761124978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7438-9141","authenticated-orcid":false,"given":"Clara","family":"Aguilar-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J.","family":"Lenaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Villellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Guillemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Ammerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8388-5892","authenticated-orcid":false,"given":"Guillaume","family":"Golovkine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Sordello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-5069","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Chauffour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Cuc","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8985-9265","authenticated-orcid":false,"given":"Taane G.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyean","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongjun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Crabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Esquivias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacer","family":"Lounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Amssoms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Bartolome-Nebreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Gruppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7157-4034","authenticated-orcid":false,"given":"Gregory T.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Upton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-9889","authenticated-orcid":false,"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Ballell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5542-4568","authenticated-orcid":false,"given":"Anil","family":"Koul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Pym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-3187","authenticated-orcid":false,"given":"Richard J.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-9026","authenticated-orcid":false,"given":"Dirk A.","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"64427_CR1","unstructured":"World Health Organisation. Global Tuberculosis report 2024. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023 (2024)."},{"key":"64427_CR2","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"B-T Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa, B.-T. et al. A 24\u2009week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med. 387, 2331\u20132343 (2022).","journal-title":"N. Engl. J. Med."},{"key":"64427_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"B-T Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa, B.-T. et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.  Lancet Respir. Med. 12, 117\u2013128 (2024).","journal-title":"Lancet Respir. Med."},{"key":"64427_CR4","unstructured":"World Health Organisation. Who Consolidated Guidelines On Tuberculosis. Module 4: Treatment - Drug-resistant Tuberculosis Treatment. https:\/\/www.who.int\/publications\/i\/item\/9789240063129 (2022)."},{"key":"64427_CR5","unstructured":"World Health Organisation. Key Updates To The Treatment Of Drug-resistant Tuberculosis - Rapid Communication. https:\/\/www.who.int\/publications\/i\/item\/WHO-UCN-TB-2022-2 (2024)."},{"key":"64427_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70535-y","volume":"14","author":"VJ Nehru","year":"2024","unstructured":"Nehru, V. J. et al. Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study. Sci. Rep. 14, 19719 (2024).","journal-title":"Sci. Rep."},{"key":"64427_CR7","unstructured":"Stop T. B. Partnership. Clinical Pipeline. https:\/\/www.newtbdrugs.org\/pipeline\/clinical (2024)."},{"key":"64427_CR8","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/AAC.01411-05","volume":"50","author":"EE McKee","year":"2006","unstructured":"McKee, E. E., Ferguson, M., Bentley, A. T. & Marks, T. A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50, 2042\u20132049 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64427_CR9","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1093\/cid\/ciac485","volume":"76","author":"J Eimer","year":"2023","unstructured":"Eimer, J. et al. Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment. Clin. Infect. Dis. 76, e947\u2013e956 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"64427_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5588\/ijtld.22.0632","volume":"27","author":"D Vengurlekar","year":"2023","unstructured":"Vengurlekar, D. et al. Linezolid resistance in patients with drug-resistant TB. Int J. Tuberc. Lung Dis. 27, 567\u2013569 (2023).","journal-title":"Int J. Tuberc. Lung Dis."},{"key":"64427_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/jac\/dkac019","volume":"77","author":"S Wasserman","year":"2022","unstructured":"Wasserman, S. et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J. Antimicrob. Chemother. 77, 1146\u20131154 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"64427_CR12","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMc1913327","volume":"382","author":"VR de Jager","year":"2020","unstructured":"de Jager, V. R. et al. Telacebec (Q203), a new antituberculosis agent. N. Engl. J. Med 382, 1280\u20131281 (2020).","journal-title":"N. Engl. J. Med"},{"key":"64427_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1021\/acsinfecdis.7b00112","volume":"3","author":"NS Chandrasekera","year":"2017","unstructured":"Chandrasekera, N. S. et al. Improved phenoxyalkylbenzimidazoles with activity against mycobacterium tuberculosis appear to target QcrB. ACS Infect. Dis. 3, 898\u2013916 (2017).","journal-title":"ACS Infect. Dis."},{"key":"64427_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","volume":"19","author":"K Pethe","year":"2013","unstructured":"Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157\u20131160 (2013).","journal-title":"Nat. Med."},{"key":"64427_CR15","doi-asserted-by":"crossref","unstructured":"Janssen S. et al. Telacebec, a potent agent in the fight against tuberculosis: findings from a randomized, phase 2 clinical trial and beyond. Am. J. Respir. Crit. Care Med. 211, 1504\u22121512 (2025).","DOI":"10.1164\/rccm.202408-1632OC"},{"key":"64427_CR16","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1128\/AAC.03486-14","volume":"58","author":"K Arora","year":"2014","unstructured":"Arora, K. et al. Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis. Antimicrobial. Agents Chemother. 58, 6962\u20136965 (2014).","journal-title":"Antimicrobial. Agents Chemother."},{"key":"64427_CR17","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s11030-021-10335-y","volume":"26","author":"MA Wani","year":"2022","unstructured":"Wani, M. A. & Dhaked, D. K. Targeting the cytochrome bc(1) complex for drug development in M. tuberculosis: review. Mol. Divers 26, 2949\u20132965 (2022).","journal-title":"Mol. Divers"},{"key":"64427_CR18","doi-asserted-by":"crossref","unstructured":"Lamers M. et. al. Structural and mechanistic study of a novel inhibitor of M. tuberculosis cytochrome bc1:aa3. NPJ Drug Discov. 2, 6 (2025).","DOI":"10.21203\/rs.3.rs-5630670\/v1"},{"key":"64427_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa2212537","volume":"388","author":"NI Paton","year":"2023","unstructured":"Paton, N. I. et al. Treatment strategy for rifampin-susceptible tuberculosis. N. Engl. J. Med. 388, 873\u2013887 (2023).","journal-title":"N. Engl. J. Med."},{"key":"64427_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12393","volume":"7","author":"DA Lamprecht","year":"2016","unstructured":"Lamprecht, D. A. et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat. Commun. 7, 12393 (2016).","journal-title":"Nat. Commun."},{"key":"64427_CR21","doi-asserted-by":"publisher","first-page":"a017822","DOI":"10.1101\/cshperspect.a017822","volume":"5","author":"G Sotgiu","year":"2015","unstructured":"Sotgiu, G., Centis, R., D\u2019Ambrosio, L. & Migliori, G. B. Tuberculosis treatment and drug regimens. Cold Spring Harb. Perspect. Med 5, a017822 (2015).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"64427_CR22","unstructured":"EU Clinical Trial (2023-508810-41-00). A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants. https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2023-508810-41-00 (2024)."},{"key":"64427_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","volume":"191","author":"AH Diacon","year":"2015","unstructured":"Diacon, A. H. et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am. J. Respir. Crit. Care Med. 191, 943\u2013953 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"64427_CR24","first-page":"e00962","volume":"69","author":"D Komm Oliver","year":"2024","unstructured":"Komm Oliver, D. et al. Contribution of telacebec to novel drug regimens in a murine tuberculosis model. Antimicrobial. Agents Chemother. 69, e00962\u201300924 (2024).","journal-title":"Antimicrobial. Agents Chemother."},{"key":"64427_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44887-9","volume":"9","author":"NP Kalia","year":"2019","unstructured":"Kalia, N. P. et al. Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc1:aa3 in Mycobacterium tuberculosis. Sci. Rep. 9, 8608 (2019).","journal-title":"Sci. Rep."},{"key":"64427_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s15010-024-02424-5","volume":"53","author":"R Idris","year":"2025","unstructured":"Idris, R. et al. Sex-dependent variability of isoniazid and rifampicin serum levels in patients with tuberculosis. Infection 53, 1051\u20131060 (2025).","journal-title":"Infection"},{"key":"64427_CR27","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3389\/fimmu.2017.01806","volume":"8","author":"M Chamekh","year":"2017","unstructured":"Chamekh, M. et al. Differential susceptibility to infectious respiratory diseases between males and females linked to sex-specific innate immune inflammatory response. Front Immunol. 8, 1806 (2017).","journal-title":"Front Immunol."},{"key":"64427_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61503-3","volume":"10","author":"D Hertz","year":"2020","unstructured":"Hertz, D., Dibbern, J., Eggers, L., von Borstel, L. & Schneider, B. E. Increased male susceptibility to Mycobacterium tuberculosis infection is associated with smaller B cell follicles in the lungs. Sci. Rep. 10, 5142 (2020).","journal-title":"Sci. Rep."},{"key":"64427_CR29","unstructured":"TB Alliance. New Clinical Trial Examines Use Of Novel Compound Telacebec In Buruli Ulcer Patients. https:\/\/www.tballiance.org\/news-new-clinical-trial-examines-use-novel-compound-telacebec-buruli-ulcer-patients\/ (2024)."},{"key":"64427_CR30","doi-asserted-by":"crossref","unstructured":"Almeida D. V. et al. Telacebec for ultrashort treatment of buruli ulcer in a mouse model. Antimicrob Agents Chemother 64, e00259\u221220 (2020).","DOI":"10.1128\/AAC.00259-20"},{"key":"64427_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3201\/eid2803.210394","volume":"28","author":"R Lahiri","year":"2022","unstructured":"Lahiri, R., Adams, L. B., Thomas, S. S. & Pethe, K. Sensitivity of Mycobacterium leprae to telacebec. Emerg. Infect. Dis. 28, 749\u2013751 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"64427_CR32","doi-asserted-by":"crossref","unstructured":"Cokol M., Kuru N., Bicak E., Larkins-Ford J., Aldridge B. B. Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. Sci. Adv. 3, e1701881 (2024).","DOI":"10.1126\/sciadv.1701881"},{"key":"64427_CR33","doi-asserted-by":"crossref","unstructured":"Sarathy J. P. et al. Extreme drug tolerance of Mycobacterium tuberculosis in caseum. Antimicrob. Agents Chemother. 62, e02266\u221217. (2018).","DOI":"10.1128\/AAC.02266-17"},{"key":"64427_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22833-6","volume":"12","author":"ND Walter","year":"2021","unstructured":"Walter, N. D. et al. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nat. Commun. 12, 2899 (2021).","journal-title":"Nat. Commun."},{"key":"64427_CR35","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1128\/AAC.00105-15","volume":"59","author":"SY Li","year":"2015","unstructured":"Li, S. Y. et al. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob. Agents Chemother. 59, 4026\u20134030 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64427_CR36","doi-asserted-by":"crossref","unstructured":"Kort F. et al. Fully weekly antituberculosis regimen: a proof-of-concept study. Eur. Respir. J. 56, 1902502 (2020).","DOI":"10.1183\/13993003.02502-2019"},{"key":"64427_CR37","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/acsinfecdis.0c00252","volume":"6","author":"JN Akester","year":"2020","unstructured":"Akester, J. N. et al. Synthesis, structure-activity relationship, and mechanistic studies of aminoquinazolinones displaying antimycobacterial activity. ACS Infect. Dis. 6, 1951\u20131964 (2020).","journal-title":"ACS Infect. Dis."},{"key":"64427_CR38","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1021\/acsomega.0c05589","volume":"6","author":"PC Ray","year":"2021","unstructured":"Ray, P. C. et al. Spirocycle MmpL3 inhibitors with improved hERG and cytotoxicity profiles as Inhibitors of Mycobacterium tuberculosis growth. ACS Omega 6, 2284\u20132311 (2021).","journal-title":"ACS Omega"},{"key":"64427_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41586-025-09177-7","volume":"644","author":"DA Lamprecht","year":"2025","unstructured":"Lamprecht, D. A. et al. Targeting de novo purine biosynthesis for tuberculosis treatment. Nature 644, 214\u2013220 (2025).","journal-title":"Nature"},{"key":"64427_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41692-2","volume":"9","author":"PJ Gomez-Gonzalez","year":"2019","unstructured":"Gomez-Gonzalez, P. J. et al. An integrated whole genome analysis of Mycobacterium tuberculosis reveals insights into relationship between its genome, transcriptome and methylome. Sci. Rep. 9, 5204 (2019).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64427-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64427-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64427-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:23:04Z","timestamp":1761124984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64427-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64427"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64427-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5331796\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.G., C.V. and D.A.L. have been named inventors in a patent application for JNJ-2901 and JNJ-4052 compounds. C.A.-P., C.V., J.G., M.C., J.E., N.L., B.S., J.M.B.-N., V.C., LBallell, B.B., A.K., A.S.P. and D.A.L. were\/are all full-time employees of Janssen, a Johnson & Johnson company, and\/or potential stockholders of Johnson & Johnson. G.G., LBrock, S.S. and A.U. were\/are all full-time employees of Evotec. K.N., J.K. and J.C. were\/are full-time employees of Qurient Co. Ltd. J.D., H.P., A.H., A.K., A.J.L., G.T.R., N.C.A., V.G., E.L.N. and R.J.W. received funding from Janssen Pharmaceutica to perform contract research. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9344"}}